Photo of Tom Powles taken from bartscancer.london
May 27, 2024, 05:34
Tom Powles: The ASCO 24 highlight In My Opinion
Tom Powles, Director of Barts Cancer Center, shared on X:
“The ASCO 24 highlight IMO. Currently 3 peri-operative IO approaches: adjuvant, neoadjuvant or both. NADINE tests neoadjuvant vs adjuvant. If +ve and neoadjuvant IO >adjuvant then shorter stronger peri-operative IO maybe better than longer adjuvant/combined approaches(+/- ctDNA)”
Source: Tom Powles/X
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023
Nov 14, 2024, 00:19
Nov 14, 2024, 00:02
Nov 13, 2024, 23:57
Nov 13, 2024, 23:54
Nov 13, 2024, 23:48
Nov 13, 2024, 23:46